Thyrocare Technologies growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+20.6%+20.2%+8.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+37.7%+38.5%+14.5%
+50.6%+49.4%+11.2%
+79.4%+30.6%+8.0%
−40.0%+27.6%+10.4%
+7.9%+7.6%+1.8%
+7.1%+3.7%−1.4%
+11.5%+14.1%+29.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

THYROCARE₹466.65

Thyrocare Technologies Ltd.

· Pharma & Health
₹ CrorePeersLALPATHLABMETROPOLISVIJAYASUPRIYAVIYASHSTARSPARCYATHARTHMcap ₹7,428 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+8.6+20.2+20.6—
EBITDA Growth—+14.5+38.5+37.7—
EBIT Growth—+11.2+49.4+50.6—
Net Income Growth—+8.0+30.6+79.4—
EPS Growth—+10.4+27.6-40.0—
Total Assets Growth—+1.8+7.6+7.9—
Total Equity Growth—-1.4+3.7+7.1—
Cash from Operations Growth—+29.6+14.1+11.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.